Concepts, considerations, and concerns on the cutting edge of radiofrequency ablation

Journal of Vascular and Interventional Radiology

Volumn 16, Issue 5, 2005, Pages 597-613

  Brown, Daniel B ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENAL CORTEX CARCINOMA; BONE METASTASIS; BONE PAIN; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER INCIDENCE; CRYOTHERAPY; DIAGNOSTIC IMAGING; FOLLOW UP; HEMATURIA; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; LIVER TUMOR; LUNG TUMOR; NEPHRECTOMY; OSTEOID OSTEOMA; PAIN; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; SMALL CELL CARCINOMA; STANDARD; THERMAL INJURY; TISSUE STRUCTURE; TREATMENT OUTCOME;

EID: 18444393449     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.RVI.0000156097.63027.7B     Document Type: Review

References (115)

1. Shetty SK, Rosen MP, Raptopoulos V, Goldberg SN. Cost-effectiveness of percutaneous radiofrequency ablation for malignant hepatic neoplasms. J Vasc Interv Radiol 2001; 12:823-833.
2. Solbiati L, Livraghi T, Goldberg SN, et al. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 2001; 221:159-166.
3. Curley SA, Izzo F, Delrio P, et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg 1999; 230:1-8.
4. Goldberg SN, Dupuy DE. Image-guided radiofrequency tumor ablation: challenges and opportunities - part I. J Vasc Interv Radiol 2001; 12:1021-1032.
5. Dupuy DE, Goldberg SN. Image-guided radiofrequency tumor ablation: challenges and opportunities - part II. J Vasc Interv Radiol 2001; 12:1135-1148.
6. Ahmed M, Liu Z, Afzal KS, et al. Radiofrequency ablation: effect of surrounding tissue composition on coagulation necrosis in a canine tumor model. Radiology 2004; 230:761-767.
7. Goldberg SN, Gazelle GS, Mueller PR. Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance. AJR Am J Roentgenol 2000; 174:323-331.
8. Hwang JJ, Walther MM, Pautler SE, et al. Radiofrequency ablation of small renal tumors: intermediate results. J Urol 2004; 171:1814-1818.
9. Pavlovich CP, Walther MM, Choyke PL, et al. Percutaneous radiofrequency ablation of small renal tumors: initial results. J Urol 2002; 167:10-15.
10. Jeffrey SS, Birdwell RL, Ikeda DM, et al. Radiofrequency ablation of breast cancer: first report of an emerging technology. Arch Surg 1999; 134:1064-1068.
11. Gervais DA, McGovern FJ, Arellano RS, McDougal WS, Mueller PR. Renal cell carcinoma: clinical experience and technical success with radio-frequency ablation of 42 tumors. Radiology 2003; 226:417-424.
12. Rossi S, Garbagnati F, Lencioni R, et al. Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology 2000; 217:119-126.
13. Yamakado K, Nakatsuka A, Ohmori S, et al. Radiofrequency ablation combined with chemoembolization in hepatocellular carcinoma: treatment response based on tumor size and morphology. J Vasc Interv Radiol 2002; 13:1225-1232.
14. Chang I, Mikityansky I, Wray-Cahen D, Pritchard WF, Karanian JW, Wood BJ. Effects of perfusion on radiofrequency ablation in swine kidneys. Radiology 2004; 231:500-505.
15. Aschoff AJ, Sulman A, Martinez M, et al. Perfusion-modulated MR imaging-guided radiofrequency ablation of the kidney in a porcine model. AJR Am J Roentgenol 2001; 177:151-158.
16. Horkan C, Ahmed M, Liu Z, et al. Radiofrequency ablation: effect of pharmacologic modulation of hepatic and renal blood flow on coagulation diameter in a VX2 tumor model. J Vasc Interv Radiol 2004; 15:269-274.
17. Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19:3852-3860.
18. Griffin RJ, Lee SH, Rood KL, et al. Use of arsenic trioxide as an antivascular and thermosensitizing agent in solid tumors. Neoplasia 2000; 2:555-560.
19. Matlaga BR, Zagoria RJ, Woodruff RD, Torti FM, Hall MC. Phase II trial of radio frequency ablation of renal cancer: evaluation of the kill zone. J Urol 2002; 168:2401-2405.
20. Zagoria RJ, Hawkins AD, Clark PE, et al. Percutaneous CT-guided radiofrequency ablation of renal neoplasms: factors influencing success. AJR Am J Roentgenol 2004; 183:201-207.
21. Linehan WM. Editorial: Kidney cancer - a unique opportunity for the development of disease specific therapy. J Urol 2002; 168:2411-2412.
22. Mayo-Smith WW, Dupuy DE, Parikh PM, Pezzullo JA, Cronan JJ. Imaging-guided percutaneous radiofrequency ablation of solid renal masses: techniques and outcomes of 38 treatment sessions in 32 consecutive patients. AJR Am J Roentgenol 2003; 180:1503-1508.
23. Hartmann JT, Bokemeyer C. Chemotherapy for renal cell carcinoma. Anticancer Res 1999; 19:1541-1543.
24. Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol 2000; 27:177-186.
25. Mabjeesh NJ, Avidor Y, Matzkin H. Emerging nephron sparing treatments for kidney tumors: a continuum of modalities from energy ablation to laparoscopic partial nephrectomy. J Urol 2004; 171:553-560.
26. Makhoul B, De La Taille A, Vordos D, et al. Laparoscopic radical nephrectomy for T1 renal cancer: the gold standard? A comparison of laparoscopic vs open nephrectomy. BJU Int 2004; 93:67-70.
27. Lee CT, Katz J, Shi W, Thaler HT, Reuter VE, Russo P. Surgical management of renal tumors 4 cm. or less in a contemporary cohort. J Urol 2000; 163:730-736.
28. Kavoussi LR, Kerbl K, Capelouto CC, McDougall EM, Clayman RV. Laparoscopic nephrectomy for renal neoplasms. Urology 1993; 42:603-609.
29. Morgan WR, Zincke H. Progression and survival after renal-conserving surgery for renal cell carcinoma: experience in 104 patients and extended followup. J Urol 1990; 144:852-857.
30. Licht MR, Novick AC. Nephron sparing surgery for renal cell carcinoma. J Urol 1993; 149:1-7.
31. Fergany AF, Hafez KS, Novick AC. Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup. J Urol 2000; 163:442-445.
32. Lau WK, Blute ML, Weaver AL, Torres VE, Zincke H. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc 2000; 75:1236-1242.
33. McDougall EM, Elbahnasy AM, Clayman RV. Laparoscopic wedge resection and partial nephrectomy - the Washington University experience and review of the literature. JSLS 1998; 2:15-23.
34. Gill IS, Desai MM, Kaouk JH, et al. Laparoscopic partial nephrectomy for renal tumor: duplicating open surgical techniques. J Urol 2002; 167:469-477.
35. Jeschke K, Peschel R, Wakonig J, Schellander L, Bartsch G, Henning K. Laparoscopic nephron-sparing surgery for renal tumors. Urology 2001; 58:688-692.
36. Zlotta AR, Wildschutz T, Raviv G, et al. Radiofrequency interstitial tumor ablation (RITA) is a possible new modality for treatment of renal cancer: ex vivo and in vivo experience. J Endourol 1997; 11:251-258.
37. Ogan K, Jacomides L, Dolmatch BL, et al. Percutaneous radiofrequency ablation of renal tumors: technique, limitations, and morbidity. Urology 2002; 60:954-958.
38. Michaels MJ, Rhee HK, Mourtzinos AP, Summerhayes IC, Silverman ML, Libertino JA. Incomplete renal tumor destruction using radio frequency interstitial ablation. J Urol 2002; 168:2406-2409.
39. Rendon RA, Kachura JR, Sweet JM, et al. The uncertainty of radio frequency treatment of renal cell carcinoma: findings at immediate and delayed nephrectomy. J Urol 2002; 167:1587-1592.
40. Roy-Choudhury SH, Cast JE, Cooksey G, Puri S, Breen DJ. Early experience with percutaneous radiofrequency ablation of small solid renal masses. AJR Am J Roentgenol 2003; 180:1055-1061.
41. Su LM, Jarrett TW, Chan DY, Kavoussi LR, Solomon SB. Percutaneous computed tomography-guided radiofrequency ablation of renal masses in high surgical risk patients: preliminary results. Urology 2003; 61:26-33.
42. Farrell MA, Charboneau WJ, DiMarco DS, et al. Imaging-guided radiofrequency ablation of solid renal tumors. AJR Am J Roentgenol 2003; 180:1509-1513.
43. Corwin TS, Lindberg G, Traxer O, et al. Laparoscopic radiofrequency thermal ablation of renal tissue with and without hilar occlusion. J Urol 2001; 166:281-284.
44. Liszczak TM, Hedley-Whyte ET, Adams JF, et al. Limitations of tetrazolium salts in delineating infarcted brain. Acta Neuropathol 1984; 65:150-157.
45. Uzzo RG, Novick AC. Nephron sparing surgery for renal tumors: indications, techniques and outcomes. J Urol 2001; 166:6-18.
46. Collyer WC, Landman J, Olweny EO, et al. Comparison of renal ablation with cryotherapy, dry radiofrequency, and saline augmented radiofrequency in a porcine model. J Am Coll Surg 2001; 193:505-513.
47. Gill IS, Novick AC, Meraney AM, et al. Laparoscopic renal cryoablation in 32 patients. Urology 2000; 56:748-753.
48. Rukstalis DB, Khorsandi M, Garcia FU, Hoenig DM, Cohen JK. Clinical experience with open renal cryoablation. Urology 2001; 57:34-39.
49. Lee DI, McGinnis DE, Feld R, Strup SE. Retroperitoneal laparoscopic cryoablation of small renal tumors: intermediate results. Urology 2003; 61:83-88.
50. Shingleton WB, Sewell PE. Cryoablation of renal tumours in patients with solitary kidneys. BJU Int 2003; 92:237-239.
51. Wood BJ, Abraham J, Hvizda JL, Alexander HR, Fojo T. Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer 2003; 97:554-560.
52. Luton JP, Gerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990; 322:1195-1201.
53. Wooten MD, King DK. Adrenal cortical carcinoma: epidemiology and treatment with mitotane and a review of the literature. Cancer 1993; 72:3145-3155.
54. Vassilopoulou-Sellin R, Guinee VF, Klein MJ, et al. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 1993; 71:3119-3123.
55. Kim SH, Brennan MF, Russo P, Burt ME, Coit DG. The role of surgery in the treatment of clinically isolated adrenal metastasis. Cancer 1998; 82:389-394.
56. Lo CY, van Heerden JA, Soreide JA, et al. Adrenalectomy for metastatic disease to the adrenal glands. Br J Surg 1996; 83:528-531.
57. Mayo-Smith WW, Dupuy DE. Adrenal neoplasms: CT-guided radiofrequency ablation - preliminary results. Radiology 2004; 231:225-230.
58. Pacak K, Fojo T, Goldstein DS, et al. Radiofrequency ablation: a novel approach for treatment of metastatic pheochromocytoma. J Natl Cancer Inst 2001; 93:648-649.
59. Ahrar K. The role and limitations of radiofrequency ablation in treatment of bone and soft tissue tumors. Curr Oncol Rep 2004; 6:315-320.
60. Kneisl J, Simon M. Medical management compared with operative treatment for osteoid-osteoma. J Bone Joint Surg Am 1992; 74:179-185.
61. Rosenthal DI, Hornicek FJ, Wolfe MVV, Jennings LC, Gebhardt MC, Mankin HJ. Percutaneous radiofrequency coagulation of osteoid osteoma compared with operative treatment. J Bone Joint Surg Am 1998; 80:815-821.
62. Harcke HT, Conway JJ, Tachdjian MO, et al. Scintigraphic localization of bone lesions during surgery. Skeletal Radiol 1985; 13:211-216.
63. Osebold WR, Lester EL, Hurley JH, Vincent RL. Intraoperative use of the mobile gamma camera in localizing and excising osteoid osteomas of the spine. Spine 1993; 18:1816-1828.
64. Towbin R, Kaye R, Meza M, Pollock A, Yaw K, Moreland M. Osteoid osteoma: percutaneous excision using a CT-guided coaxial technique. AJR Am J Roentgenol 1995; 164:945-949.
65. Sans N, Galy-Fourcade D, Assoun J, et al. Osteoid osteoma: CT-guided percutaneous resection and follow-up in 38 patients. Radiology 1999; 212:687-692.
66. Roger B, Bellin M, Wioland M, Grenier P. Osteoid osteoma: CT-guided percutaneous excision confirmed with immediate follow-up scintigraphy in 16 outpatients. Radiology 1996; 201:239-242.
67. Assoun J, Railhac J, Bonnevialle P, et al. Osteoid osteoma: percutaneous resection with CT guidance. Radiology 1993; 188:541-547.
68. Woertler K, Vestring T, Boettner F, Winkelmann W, Heindel W, Lindner N. Osteoid osteoma: CT-guided percutaneous radiofrequency ablation and follow-up in 47 patients. J Vasc Interv Radiol 2001; 12:717-722.
69. Rosenthal D, Alexander A, Rosenberg A, Springfield D. Ablation of osteoid osteomas with a percutaneously placed electrode: a new procedure. Radiology 1992; 183:29-33.
70. Rosenthal DI, Hornicek FJ, Torriani M, Gebhardt MC, Mankin HJ. Osteoid osteoma: percutaneous treatment with radiofrequency energy. Radiology 2003; 229:171-175.
71. Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80:1588-1594.
72. Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994; 330:592-596.
73. Gunawardana DH, Lichtenstein M, Better N, Rosenthal M. Results of strontium-89 therapy in patients with prostate cancer resistant to chemotherapy. Clin Nucl Med 2004; 29:81-85.
74. Ashayeri E, Omogbehin A, Sridhar R, Shankar RA. Strontium 89 in the treatment of pain due to diffuse osseous metastases: a university hospital experience. J Natl Med Assoc 2002; 94:706-711.
75. Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004; 90:1133-1137.
76. Coukell AJ, Markham A. Pamidronate: a review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone. Drugs Aging 1998; 12:149-168.
77. Hillner BE, Weeks JC, Desch CE, Smith TJ. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2000; 18:72-79.
78. Hortobagyi GN. Novel approaches to the management of bone metastases. Semin Oncol 2003; 30:161-166.
79. Jagdev SP, Purohit P, Heatley S, Herling C, Coleman RE. Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol 2001; 12:1433-1438.
80. Janjan NA. Radiation for bone metastases: conventional techniques and the role of systemic radiopharmaceuticals. Cancer 1997; 80:1628-1645.
81. Janjan N. Bone metastases: approaches to management. Semin Oncol 2001; 28:28-34.
82. Maisano R, Pergolizzi S, Cascinu S. Novel therapeutic approaches to cancer patients with bone metastasis. Crit Rev Oncol Hematol 2001; 40:239-250.
83. Sharma DN, Gairola M, Mohanti BK, Rath GK. Radiation therapy in skeletal metastases. Med J Malaysia 1999; 54:210-215.
84. Tong D, Gillick L, Hendrickson FR. The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group. Cancer 1982; 50:893-899.
85. Body JJ. Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions. Breast 2003; 12:537-44.
86. Conte PF, Latreille J, Mauriac L, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol 1996; 14:2552-2559.
87. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lyric bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999; 17:846-854.
88. Romanus D, Iscoe N, DeAngelis C, Shear N, Einarson TR. Cost analysis of secondary prophylaxis with oral clodronate versus pamidronate in metastatic breast cancer patients. Support Care Cancer 2004; 12:844-851.
89. Falkmer U, Jarhult J, Wersall P, Cavallin-Stahl E. A systematic overview of radiation therapy effects in skeletal metastases. Acta Oncol 2003; 42:620-633.
90. Ratanatharathorn V, Powers WE, Moss WT, Perez CA. Bone metastasis: review and critical analysis of random allocation trials of local field treatment. Int J Radiat Oncol Biol Phys 1999; 44:1-18.
91. Callstrom MR, Charboneau JW, Goetz MP, et al. Painful metastases involving bone: feasibility of percutaneous CT- and US-guided radio-frequency ablation. Radiology 2002; 224:87-97.
92. Goetz MP, Callstrom MR, Charboneau JW, et al. Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study. J Clin Oncol 2004; 22:300-306.
93. Cotten A, Dewatre F, Cortet B, et al. Percutaneous vertebroplasty for osteolytic metastases and myeloma: effects of the percentage of lesion filling and the leakage of methyl methacrylate at clinical follow-up. Radiology 1996; 200:525-530.
94. Gronemeyer DH, Schirp S, Gevargez A. Image-guided radiofrequency ablation of spinal tumors: preliminary experience with an expandable array electrode. Cancer J 2002; 8:33-39.
95. Nakatsuka A, Yamakado K, Maeda M, et al. Radiofrequency ablation combined with bone cement injection for the treatment of bone malignancies. J Vasc Interv Radiol 2004; 15:707-712.
96. Nour SG, Aschoff AJ, Mitchell ICS, Emancipator SN, Duerk JL, Lewin JS. MR imaging-guided radio-frequency thermal ablation of the lumbar vertebrae in porcine models. Radiology 2002; 224:452-462.
97. Fourney DR, Schomer DF, Nader R, et al. Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. J Neurosurg Spine 2003; 98:21-30.
98. Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1995; 333:1456-1461.
99. Fisher B, Redmond C, Poisson R, et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1989; 320:822-828.
100. Hayashi AH, Silver SF, van der Westhuizen NG, et al. Treatment of invasive breast carcinoma with ultrasound-guided radiofrequency ablation. Am J Surg 2003; 185:429-435.
101. Izzo F, Thomas R, Delrio P, et al. Radiofrequency ablation in patients with primary breast carcinoma: a pilot study in 26 patients. Cancer 2001; 92:2036-2044.
102. Burak WE, Agnese DM, Povoski SP, et al. Radiofrequency ablation of invasive breast carcinoma followed by delayed surgical excision. Cancer 2003; 98:1369-1376.
103. Fornage BD, Sneige N, Ross MI, et al. Small (< or = 2-cm) breast cancer treated with US-guided radiofrequency ablation: feasibility study. Radiology 2004; 231:215-224.
104. Dupuy DE, Monchik JM, Decrea C, Pisharodi L. Radiofrequency ablation of regional recurrence from well-differentiated thyroid malignancy. Surgery 2001; 130:971-977.
105. Marangio A, Prati U, Luinetti O, Brunetti E, Filice C. Radiofrequency ablation of colorectal splenic metastasis. AJR Am J Roentgenol 2002; 178:1481-1482.
106. Wood BJ, Bates S. Radiofrequency thermal ablation of a splenic metastasis. J Vasc Interv Radiol 2001; 12:261-263.
107. Nakada SY, Jerde TJ, Warner TF, et al. Bipolar radiofrequency ablation of the kidney: comparison with monopolar radiofrequency ablation. J Endourol 2003; 17:927-933.
108. Lee JM, Han JK, Kim SH, Lee JY, Choi SH, Choi BI. Hepatic bipolar radiofrequency ablation using perfused-cooled electrodes: a comparative study in the ex vivo bovine liver. Br J Radiol 2004; 77:944-949.
109. Dick EA, Joarder R, De Jode MG, Wragg P, Vale JA, Gedroyc WM. Magnetic resonance imaging-guided laser thermal ablation of renal tumours. BJU Int 2002; 90:814-822.
110. Mack MG, Straub R, Eichler K, Sollner O, Lehnert T, Vogl TJ. Breast cancer metastases in liver: laser-induced interstitial thermotherapy - local tumor control rate and survival data. Radiology 2004; 233:400-409.
111. Aramaki M, Kawano K, Ohno T, et al. Microwave coagulation therapy for unresectable hepatocellular carcinoma. Hepatogastroenterology 2004; 51:1784-1787.
112. Vogl TJ, Straub R, Eichler K, Sollner O, Mack MG. Colorectal carcinoma metastases in liver: laser-induced interstitial thermotherapy - local tumor control rate and survival data. Radiology 2004; 230:450-458.
113. Seifert JK, Junginger T. Prognostic factors for cryotherapy of colorectal liver metastases. Eur J Surg Oncol 2004; 30:34-40.
114. Clement GT. Perspectives in clinical uses of high-intensity focused ultrasound. Ultrasonics 2004; 42:1087-1093.
115. Kennedy JE, Ter Haar GR, Cranston D. High intensity focused ultrasound: surgery of the future? Br J Radiol 2003; 76:590-599.